Takeda Pharmaceutical (TAK) Restructuring Costs (2019)
Takeda Pharmaceutical (TAK) posted Restructuring Costs of $113.9 million for Q1 2019.
Powered by 
Analysis
Takeda Pharmaceutical (TAK) Restructuring Costs (2019) Analysis & Trends
Takeda Pharmaceutical has reported Restructuring Costs for 1 years, with the latest figure at $113.9 million in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.71 Bn | 625.95 Bn | 17.26 Bn |
| 2 | AbbVie | 442.22 Bn | 435.65 Bn | 12.70 Bn |
| 3 | Merck | 366.92 Bn | 359.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.90 Bn | 259.21 Bn | 11.24 Bn |
| 5 | Pfizer | 159.20 Bn | 147.50 Bn | 10.94 Bn |
| 6 | Sanofi | 52.44 Bn | 45.06 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.11 Bn | 44.11 Bn | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.50 Bn | 18.84 Bn | 683.80 Mn |
| 10 | Takeda Pharmaceutical | 2.62 Bn | -3.18 Bn | 5.10 Bn |